中國生物製藥(01177.HK):鎮痛和微循環領域治療藥物“利馬前列素片”獲批上市
格隆匯2月20日丨中國生物製藥(01177.HK)發佈公吿,集團開發的鎮痛和微循環領域治療藥物“利馬前列素片”(凱立通)獲得中國國家藥品監督管理局頒發藥品註冊證書。利馬前列素片是目前臨牀唯一在説明書中明確適應症為腰椎管狹窄症治療的小分子化藥,是國內首個針對腰椎管狹窄症病理機制,兼具改善神經血流微循環障礙和改善神經功能的雙重功效的藥物,為腰椎管狹窄症全程管理的基礎用藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.